openPR Logo
Press release

FDA Device Chief Calls for Stricter Regulation of Vaginal Mesh, Other Medical Devices

03-06-2012 07:15 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen LLP

Nadrich & Cohen, LLP reports that the FDA’s chief device regulator is calling for stricter governance of vaginal mesh and other medical devices.

Los Angeles, CA, March 2, 2012 – Nadrich & Cohen, LLP reports that the U.S. Food and Drug Administration’s top medical device regulator says the federal health agency needs more power to block the approval of unsafe medical devices.

According to a recent Bloomberg report, Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, says that the agency’s current regulatory policies have created a loophole that has allowed unsafe devices to reach the market, including vaginal mesh implants and faulty metal hip replacements. A number of House Democrats introduced a bill earlier this month which would provide for more government oversight of the medical device approval process. Legislators have also appealed to key Republicans to hold congressional hearings on the safety of vaginal mesh.

Legislators are specifically concerned over the FDA’s current 510(k) approval system, which allows medical device manufacturers to seek approval for a product without conducting additional safety testing. Under the 510(k) system, a company only has to demonstrate that their product is substantially similar to an existing product already on the market. It was under this system that Johnson & Johnson was able to gain approval for its Ethicon vaginal mesh implants, which were modeled on a mesh product developed by Boston Scientific Corp. That mesh device has since been recalled from the market.

Vaginal mesh was first approved to treat stress urinary incontinence related to pelvic organ prolapse in 1996. Since 2008, the FDA has received numerous adverse event reports from consumers who say they were injured by a vaginal mesh device. The implants have been linked to a wide range of side effects, including pain, infection, scarring, tissue damage, bladder and bowel perforation, recurrence of pelvic organ prolapse and painful intercourse. In July 2011, the FDA issued an updated safety communication advising patients and health care professionals that the risks associated with transvaginal mesh may outweigh its benefits.

A number of women have subsequently filed suit against several high-profile manufacturers of vaginal mesh devices, including Johnson & Johnson, C.R. Bard and Boston Scientific. The plaintiffs claim that the companies were aware of the potential risk to women who used the mesh devices but did not adequately warn consumers of the dangers.

Women who suffered complications after being implanted with vaginal mesh are urged to seek the advice of an experienced personal injury lawyer to protect their rights. The vaginal mesh attorneys at Nadrich & Cohen, LLP are now offering confidential, no-cost consultations to women in all 50 states who believe they were harmed by one of these devices. Help is available by calling the firm’s injury hotline at 1-800-722-0765 or by completing an online case evaluation form at www.vaginalmeshlegalclaims.com.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling vaginal mesh side effects claims, Nadrich & Cohen, LLP is also investigating cases involving Yaz, Actos, DePuy Hip Implants, Zimmer Hips, Wright Conserve Hips, Pradaxa, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. All cases are accepted on a contingency basis, meaning there is never a fee unless a judgment is recovered on your behalf.

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FDA Device Chief Calls for Stricter Regulation of Vaginal Mesh, Other Medical Devices here

News-ID: 213019 • Views:

More Releases from Nadrich & Cohen LLP

Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country. Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the

All 5 Releases


More Releases for FDA

FDA Compliant Blood Storage and Preservation
Accsense Monitoring System Automates Data Archive and Alarming CAS DataLoggers provided the temperature alarming and monitoring system to a hospital blood bank looking to replace their old paper chart recorders as they became unreliable and spare parts were harder to find. For proper blood storage and preservation, the lab’s medical units needed to maintain storage temperatures between 2°C to 6°C (36°F to 43°F), given the perishability of blood components. The facility
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
FDA grants orphan drug status to Vicore
US Food and Drug Administration has awarded Vicore Pharmaceuticals with orphan Drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF). FDA’s Orphan Drug Designation program provides certain incentives for companies developing therapeutics to treat rare diseases or conditions, defined as those affecting less than 200,000 individuals in the U.S. A drug candidate and its sponsor must meet several key criteria in order to qualify for, and obtain, orphan drug
New FDA Design Control Training Courses
Salt Lake City, Utah - February 23 2017 - Procenius Consulting is a medical device consulting firm specializing solely in medical device design controls regulation (21 CFR 820.30). Announcing New Design Control Training Courses Procenius Consulting has just launched two new training courses covering basic and advanced topics of medical device design control regulation. These courses focus on compliance, practical implementation and industry best practices techniques for developing or improving a
fda online training
GRC Training Solutions provides end-to-end FDA compliance solutions for those companies who want to maximize security, minimize operational costs, improve staff productivity and stay on top of all their compliance documentation. GRC Training Solutions boasts a team of experts and specialists who have a proven track record in working with the biotechnology, medical device, diagnostic and pharmaceutical fields. Our team will work with you closely and develop solutions that meet
11-09-2016 | Science & Education
GRCTS
FDA online training
Description: Device firms, establishments or facilities that are involved in the production and distribution of medical devices intended for use in the U.S are required to register annually. Most establishments that are required to register with the FDA are also required to list the devices that are made there and the activities that are performed on those devices. Initially, FDA issued a 28-page Proposed Rule that would amend its regulations regarding